{"id":"W3088474072","doi":"10.1016/j.annonc.2020.08.1200","title":"1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Clinical endpoint; Stage (stratigraphy); Oncology; Adjuvant; Melanoma; Gastroenterology; Cancer; Immunotherapy; Randomized controlled trial; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003926232,0.0003179359,0.0006548354,0.0002594989,0.0001754156,0.0005417446,0.0002534873,0.0004050751,0.002282553],"category_scores_gemma":[0.00046213,0.0001287845,0.0007908315,0.0001659476,0.000222144,0.0004155512,0.000178247,0.0007187942,0.0003930597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000545463,"about_ca_system_score_gemma":0.0004256757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002035725,"about_ca_topic_score_gemma":0.003790305,"domain_scores_codex":[0.9998851,0.00003053853,0.000006893562,0.00002743544,0.00001385916,0.0000361538],"domain_scores_gemma":[0.9997521,0.00006884805,0.0000343415,0.00002468872,0.00001457966,0.000105521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7175534,0.01298391,0.09123778,0.0003376678,0.001509861,0.0002761733,0.0001308437,0.002168613,0.0258926,0.0002083825,0.004183611,0.1435172],"study_design_scores_gemma":[0.09608695,0.3255722,0.5390097,0.0001572488,0.005191034,0.0006799751,0.0003045168,0.008679547,0.01534579,0.0005100716,0.008372352,0.00009060314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980495,0.0007798146,0.00003755707,0.00008781125,0.00006082856,0.00002114833,0.0002990075,0.00001297929,0.0006513721],"genre_scores_gemma":[0.9971103,0.0004225504,0.00014624,0.0001432789,0.0000669458,0.00002492725,0.0009082761,0.00000737713,0.001170141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002282553,"threshold_uncertainty_score":0.007635951,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0914736239595253,"score_gpt":0.3481381117112468,"score_spread":0.2566644877517215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}